Navigation Links
DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
Date:10/26/2009

CUPERTINO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, October 29, 2009 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR®, TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation


'/>"/>
SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
4. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
5. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
6. Select Medical Holdings Corporation Announces Exercise of Underwriters Option to Purchase Additional Shares
7. Digirad Corporation to Present at BIOCOM 4th Annual Investor Conference
8. Mirixa Corporation Announces MirixaEdge(SM)
9. WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders
10. Baxa Corporation Signs Exclusive Distribution Agreement With Leading Pharmaceutical Corporation in Peoples Republic of China
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Actinic Keratosis Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Actinic Keratosis epidemiology, Actinic Keratosis market valuations ...
(Date:5/3/2016)... Research and Markets has announced ... Therapy Market Outlook 2020" report to their offering. ... ,Recombinant technology has improved significantly in past years due ... in coming years. Many cancer drugs have been developed ... are also expected to be developed with its help. ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK , ... today announced Food and Drug Administration (FDA) approval ... that provides heart failure patients with access to ... also have remote monitoring with daily automatic transmission ... heart rate in response to physiological demands. ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... 05, 2016 , ... Qrono Inc. , a specialty ... collaboration with the Australian critical medicine company, Phebra Pty Ltd. , to ... medicines can offer improved therapeutic benefits over oral formulations, including better bioavailability, improved ...
(Date:5/5/2016)... ... , ... Einstein Medical is proud to announce that it has ... commentary at the 2016 ASCRS/ASOA Symposium and Congress, which takes place in New Orleans, ... Refractive Surgery and the American Society of Ophthalmic Administrations will be held at the ...
(Date:5/5/2016)... Francisco, CA (PRWEB) , ... May 05, 2016 , ... This weekend, from Friday, May ... will take on steep California terrain at the first Team Semper Fi Mountain Bike Camp, ... Joining them will be mountain bike legends Mark Weir and Jason Moeschler, who’ll share pro ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... Business Journalists , led by the Wharton School’s most prominent professors, help ... one-day program at the Wharton School’s San Francisco campus will feature Wharton ...
(Date:5/5/2016)... ... May 05, 2016 , ... Derrin Doty Group has ... of Bremerton, Port Orchard and communities west of Seattle. The insurance provider’s caring team ... local girl who died suddenly due to complications from the flu, that they have ...
Breaking Medicine News(10 mins):